References
- Valeur E , GuéretSM, AdihouHet al. New modalities for challenging targets in drug discovery. Angew. Chem. Int. Ed. Engl.56(35), 10294–10323 (2017).
- Andersson S , AntonssonM, ElebringM, Jansson-LofmarkR, WeidolfL. Metabolism and pharmacokinetic strategies for oligonucleotide- and mRNA-based drug development. Drug Discov. Today23(10), 1733–1745 (2018).
- Ämmälä C , DruryWJ3rd, KnerrLet al. Targeted delivery of antisense oligonucleotides to pancreatic β-cells. Sci. Adv.4(10), eaat3386 (2018).
- Sander JD , JoungJK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat. Biotechnol.32(4), 347–355 (2014).
- Fellmann C , GowenBG, LinPC, DoudnaJA, CornJE. Cornerstones of CRISPR–Cas in drug discovery and therapy. Nat. Rev. Drug Discov.16, 89–100 (2017).
- Koo T , KimJS. Therapeutic applications of CRISPR RNA-guided genome editing. Brief. Funct. Genomics16, 38–45 (2017).
- ClinicalTrials.gov
- Drug Products, Including Biological Products, that Contain Nanomaterials: Guidance for Industry (December 2017). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588857.pdf
- Morgan P , BrownDG, LennardS. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat. Rev. Drug Discov.17(3), 167–181 (2018).